When Zhengye Biotechnology Holding Ltd. (ZYBT.US) completed a slightly upsized Nasdaq IPO last week by selling 1.5 million shares for $4 each, it seemed like that might be the end of its listing story. The $4 price was already at the bottom of its previously announced range, indicating tepid demand, even though the offer size was up slightly from its original plan filed last June to sell 1.25 million shares.
本月初，正业生物科技控股有限公司(ZYBT.US)以每股4美元的价格出售150万股，完成规模略有扩大的纳斯达克IPO，发行规模略高于去年6月原计划的125万股。是次以每股4美元的定价，处于之前公布的价格区间底部，当时所见，市场需求并不殷切，这似是其上市故事的结束。
您已阅读7%（543字），剩余93%（7565字）包含更多重要信息，订阅以继续探索完整内容，并享受更多专属服务。